# Zinc Carnosine

> Zinc Carnosine is a unique 1:1 chelate of zinc and L-carnosine that adheres to the gut lining. It has the strongest human evidence of any supplement for protecting intestinal permeability, while also providing direct mast cell stabilization in the GI tract where MCAS symptoms often start. ZebraThrive uses 75 mg daily, split 37.5 mg AM and PM.

**Page:** https://www.wellnessforzebras.com/ingredients/zinc-carnosine
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 75 mg daily
**Form used:** Zinc Carnosine (Polaprezinc)
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- Complete prevention of NSAID-induced permeability increase
- 70% reduction in exercise-induced gut permeability
- Dose-dependent mast cell stabilization (inhibits TNF/IL-8)
- Upregulates Type I collagen gene expression

## What it is

A unique 1:1 chelate of zinc and L-carnosine that targets the GI lining

## Why we include it

The strongest human evidence for protecting intestinal permeability while providing direct mast cell stabilization in the GI tract

## Plain-language summary

Zinc carnosine (also called polaprezinc) is a 1:1 chelated complex of zinc and L-carnosine, originally developed in Japan as a gastric ulcer drug. For the triad, it brings two distinct mechanisms: gut barrier protection (the strongest evidence base - complete prevention of NSAID-induced intestinal permeability in a clinical trial) and mast cell stabilization through both zinc-driven membrane stabilization and carnosine's antioxidant activity. We dose 37.5 mg twice daily (AM and PM) because every human RCT showing efficacy at 75 mg/day used split dosing, not once-daily. The localized mucosal mechanism requires repeated coating.

## Mechanism

Zinc carnosine increases tight junction proteins (occludin) and induces heat shock proteins (HSP70) to protect the gut lining from stress. It directly stabilizes mast cells via calcium channel blocking and membrane stabilization. For hEDS, it upregulates collagen gene expression and inhibits MMPs to protect existing collagen architecture.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Directly stabilizes mast cells and inhibits inflammatory cytokines (TNF, IL-8). Gentler than other zinc forms due to L-carnosine buffering which avoids histidine-trigger concerns.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

Supports wound healing and collagen structural integrity by upregulating collagen genes and inhibiting collagen-degrading MMPs.

### POTS (Postural Orthostatic Tachycardia Syndrome)

Crucial for exercise-intolerant patients; data shows a 70% reduction in the gut permeability caused by physical stress and temperature spikes.

## Why this form

**Selected form:** Zinc Carnosine (Polaprezinc)

Stable 1:1 chelate with 2x longer gastric residence than separate components. Targeted mucosal delivery compared to enteric coated or standard zinc salts.

**Form comparison:**

| Form | Notes | Selected |
|---|---|---|
| Polaprezinc | Stable 1:1 chelate; 2x longer mucosal contact; targeted action | Yes |
| Zinc + L-Carnosine separately | Lacks mucosal targeting; faster gastric transit | No |

## Dose protocol

| Step | Dosage | Notes |
|---|---|---|
| Week 1 | 37.5 mg daily | Check GI tolerance |
| Week 2+ | 75 mg daily | Target dose (PM) |

**Timeline to effect:** GI barrier benefits within 2-14 days; structural improvement noticeably at 4-8 weeks.

## Evidence summary

### GI Barrier Protection

Strong human RCT evidence for protecting intestinal permeability from various stresses.

- [1] **Mahmood et al., 2007.** Design: RCT, n=10. Finding: Complete prevention of the 3-fold permeability increase caused by NSAIDs.. PMID: 16777920.
- [2] **Davison et al., 2016.** Design: RCT, n=8 athletes. Finding: 70% reduction in exercise-induced gut permeability after 14 days.. PMID: 27357095.

### Mast Cell Stabilization

Inhibits mast cell degranulation and reduces histamine release in both in vitro and human-cell models.

- [4] **Gross et al., 2019.** Finding: Inhibited TNF by 60% and IL-8 by 45% in human mast cells.. PMID: 30521103.
- [3] **Cho et al., 1991.** Finding: Dose-dependent stabilization (3-30 mg/kg) in stress-induced models.. PMID: 1943472.

## Evidence gaps

No direct clinical trials in hEDS, POTS, or MCAS populations. Most data extrapolated from athletic, NSAID-user, and gastric ulcer populations.

## Safety

**Side effects:** Excellent safety record (30+ years prescription use). Mild nausea possible but rare.

**Interactions:** AVOID with Warfarin (reports of increased INR). Separate from fluoroquinolones, tetracyclines, and iron by 4-6 hours.

**Cautions:** Monitor copper status if supplementing long-term above 40mg total zinc.

**Excipients to avoid:** Iron competition

**Excipients that are safe:** HPMC capsules, Rice flour

## Frequently asked questions

### Why split into AM and PM?

Every human RCT showing zinc carnosine's gut barrier benefit used 37.5 mg twice daily. The mechanism is local mucosal coating that clears within about 2 hours, so once-daily dosing leaves a long window with no protective effect. Splitting AM and PM keeps the coating active across both digestive periods at the exact dose used in the trials.

### Is zinc carnosine the same as regular zinc?

Not exactly. The 1:1 zinc-to-carnosine chelate behaves differently from elemental zinc supplements like zinc bisglycinate or zinc gluconate. Zinc carnosine survives stomach acid, adheres to gut mucosa for about 2 hours of local contact, and releases zinc slowly at the lining - that's where the GI-protective effect comes from. About 23% of the 37.5 mg dose is elemental zinc (~8.5 mg per dose, ~17 mg/day), separate from any other zinc you take. The carnosine half contributes antioxidant activity.

### I take famotidine - is this a problem?

Yes, but it's a timing issue, not an outright conflict. H2 blockers like famotidine significantly reduce zinc absorption - the science is well-documented. Separate zinc carnosine from famotidine by at least 2 hours in either direction. Most patients on famotidine take it at bedtime; if that's your pattern, take the PM zinc carnosine with dinner (well before the famotidine) and the AM dose with breakfast. The separation is necessary; the combination is fine when timed properly.

### Is the higher-dose MMP-9 evidence concerning?

This deserves a direct answer. A 2021 study in autoimmune hepatitis patients at 150 mg/day (twice our dose, opposite tissue pathology) showed MMP-9 elevated, which raised concerns about hEDS use. We looked carefully: at 150 mg in a fibrotic-liver context, MMP-9 rises were anti-fibrotic but irrelevant to our 75 mg dose in a non-fibrotic population. MMP-1 and MMP-13 - the actual collagen-degrading enzymes in hEDS - were unaffected. We're confident at 75 mg/day; we wouldn't dose higher.

## References

[1] Mahmood et al.. (2007). Zinc carnosine for gut permeability RCT. PMID: 16777920. https://pubmed.ncbi.nlm.nih.gov/16777920/
[2] Davison et al.. (2016). Exercise-induced gut barrier protection RCT. PMID: 27357095. https://pubmed.ncbi.nlm.nih.gov/27357095/
[3] Cho et al.. (1991). Zinc carnosine mast cell stabilization. PMID: 1943472. https://pubmed.ncbi.nlm.nih.gov/1943472/
[4] Gross et al.. (2019). Anti-inflammatory effects in human mast cells. PMID: 30521103. https://pubmed.ncbi.nlm.nih.gov/30521103/
[5] Odashima et al.. (2002). HSP70 induction by zinc carnosine. PMID: 12498304. https://pubmed.ncbi.nlm.nih.gov/12498304/